Close Menu

marketing agreement

LightArray will offer a variety of Aushon's multiplex biomarker products and services in China.

Rosetta has regained US commercial rights from Prometheus for its miRview mets, miRview squamous, and miRview meso tests.

Cepheid will receive $5 million in an upfront payment and $3 million in milestone payments over the next 12 months as part of the deal, while Novartis would have exclusive global distribution rights to the test upon its commercialization in the US.

Abbott will be the exclusive distributor of the KIF6 test in the European Union and other areas that recognize the CE mark.

Waters expects the deal to result in its products being offered to a broader use base.

ARUP will begin offering the test, which measures 25 common SNPs associated with prostate cancer risk, in the fall.

Thermo Fisher's sample handling and mass spectrometers will be integrated with IBI's proprietary immunoenrichment technology, and the two firms will develop assays and workflows for the detecting and quantifying low abundance proteins.

Percorso will commercialize Generation Biotech's bead-based haplotype- and region-specific extraction technology.

Promega will sell a combined offering of kinase profiling tools from the two firms.

The firms are working on infectious disease diagnostics using Protagen's UNIarray platform.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.